郭健雄;袁进;季波;李雨;范立明;李健;石磊;龚丽娴;
GUO Jianxiong;YUAN Jin;JI Bo;LI Yu;FAN Liming;LI Jian;SHI Lei;GONG Lixian;Department of Clinical Pharmacy,General Hospital of Southern Theatre Command;Department of Nephrology,General Hospital of Southern Theatre Command;

• 1:南部战区总医院临床药学科
• 2:南部战区总医院肾脏内科

摘要(Abstract)：

目的研究标本热灭活前后对他克莫司(FK506)血药浓度是否有影响。方法收集我院最近两周器官移植患者FK506血药浓度标本共计80例,采用化学发光微粒子免疫分析法(CMIA),60例分别测定热灭活前后FK506血药浓度,20例分别测定溶血前后FK506血药浓度。结果 60例热灭活前后FK506血药浓度中,热灭活前平均血药浓度为(6.72±3.58)ng·mL~(-1),热灭活后平均血药浓度为(6.45±3.43)ng·mL~(-1),热灭活前后FK506血药浓度具有显著性差异(P<0.01,P=1.03×10~(-9)),热灭活后血药浓度普遍降低,其中降低占48例(80.00%),差值在-0.8 ng·mL~(-1)至+0.3 ng·mL~(-1)之间。溶血前后FK506血药浓度未见明显差异(P>0.05,P=0.175)。结论热灭活后FK506血药浓度普遍降低,但热灭活后平均血药浓度仅比热灭活前略低。因此,新冠肺炎疫情期间,建议对标本热灭活处理后再进行常规检测,对于保护医护工作者、减少职业暴露和节约紧缺的医疗资源等具有重要意义。
OBJECTIVE To study the effect on the blood concentrations of tacrolimus before and after thermal inactivation. METHODS Collected 80 samples from organ transplant patients to test the blood concentrations of tacrolimus by chemiluminescence microparticle immune assay(CMIA). 60 cases on the blood concentrations of tacrolimus were tested before and after thermal inactivation. 20 cases on the blood concentrations of tacrolimus were tested before and after hemolysis. RESULTS The average of blood concentration in the 60 cases was(6.72±3.58)ng·mL~(-1) before thermal inactivation. The average of blood concentration in the 60 cases was(6.45±3.43)ng·mL~(-1) after thermal inactivation. There was significant difference(P<0.01,P=1.03×10~(-9)) between the blood concentrations of tacrolimus before and after thermal inactivation. The blood concentrations were generally decreased after thermal inactivation with 48 cases(80.00%). the change of difference were between-0.8 ng·mL~(-1) to +0.3 ng·mL~(-1). There was no significant difference(P>0.05,P=0.175) between the blood concentration of tacrolimus before and after hemolysis. CONCLUSION The blood concentrations are generally decreased after thermal inactivation,but the average of blood concentrations after thermal inactivation are slightly lower than before thermal inactivation. So we suggest to test the blood concentrations of tacrolimus after thermal inactivation during COVID-19. It is good to protect the health care of workers,reduce the occupational exposure and save the scarce medical resources.

关键词(KeyWords)： 新型冠状病毒肺炎;热灭活;器官移植;他克莫司;血药浓度监测
COVID-19;thermal inactivation;organ transplantation;tacrolimus;therapeutic drug monitoring

Abstract:

Keywords:

基金项目(Foundation): 广东省医学科学技术研究基金(B2019048)

作者(Author): 郭健雄;袁进;季波;李雨;范立明;李健;石磊;龚丽娴;
GUO Jianxiong;YUAN Jin;JI Bo;LI Yu;FAN Liming;LI Jian;SHI Lei;GONG Lixian;Department of Clinical Pharmacy,General Hospital of Southern Theatre Command;Department of Nephrology,General Hospital of Southern Theatre Command;

Email:

DOI:

参考文献(References)：

• [1] 国家卫生健康委员会.新型冠状病毒肺炎诊疗方案(试行第八版)[EB/OL].http://www.nhc.gov.cn/yzygj/s7653p/202008/0a7bdf12bd4b46e5bd28ca7f9a7f5e5a/files/a449a3e2e2c94d9a856 d5faea2ff0f94.pdf.
• [2] Strategy and Policy Working Group for NCIP Epidemic Response.The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China[J].Chinese Journal of Epidemiology,2020,41(2):145-151.
• [3] 国家卫生健康委员会.2018年国家医疗服务与质量安全报告[EB/OL].http://www.nhc.gov.cn/ xwzb/ webcontroller.do?titleSeq=11197&gecstype=1.
• [4] 中华医学会器官移植学分会.器官移植免疫抑制剂临床应用技术规范(2019版)[J].器官移植,2019,10(3):213-226.
• [5] 中华医学会检验医学分会.新型冠状病毒肺炎病毒核酸检测专家共识[J].中华医学杂志,2020,100(13):968-973.
• [6] Liang H,Tan A P,Zhang S W.Effect of hemolysis in antiepileptics plasma sample determined by FPIA[J].Journal of Dalian Medical University,2008,30(5):454-455.
• [7] 唐霄,张翠欣,王伟霞.他克莫司的药代动力学特点及其影响因素新进展[J].天津药学,2019,31(3):63-68.
• [8] 胡楠,赵金飞,蒋艳,等.180例肾移植患者他克莫司血药浓度监测[J].医药导报,2018,37(12):1500-1505.
• [9] 国家药典委员会.中华人民共和国药典[M].北京:中国医药科技出版社,2015:364.
• [10] 广东省药学会.新型冠状病毒肺炎患者血药浓度检测技术指引[J].今日药学,2020,30(3):150-153.
• [11] Zhou H,Hu X H,Huang X,et al.Prevention and Control Strategy of Therapeutic Drug Monitoring Laboratory During the 2019 Novel Coronavirus Pneumonia[J].Herald of Medicine,http://kns.cnki.net/kcms/ detail/42.1293.R.20200210.2219.006.html.
• [12] 国家卫生健康委员会.新型冠状病毒肺炎实验室检测技术指南(第四版).[EB/OL].http://ww w.nhc.gov.cn/jkj/s3577/202002/573340613ab243b3a7f61df260551dd4/files/c791e5a7ea5149f680fdcb34dac0f54e.pdf.
• [13] 中华医学会检验医学分会.2019新型冠状病毒肺炎临床实验室生物安全防护专家共识[J].中华检验医学杂志,2020,43(3):203-208.